Core Insights - Sensei Biotherapeutics is advancing its lead program, solnerstotug (SNS-101), which targets the immune checkpoint VISTA, with expectations for significant clinical data updates in 2025 [1][2][4] Company Overview - Sensei Biotherapeutics is a clinical stage biotechnology company focused on developing next-generation therapeutics for cancer patients, utilizing its TMAb™ platform to create conditionally active therapeutics [4][5] Product Development - Solnerstotug (SNS-101) is designed to selectively target VISTA within the tumor microenvironment, which is associated with low survival rates in various cancer types [3][4] - The company is conducting a multi-center Phase 1/2 clinical trial to evaluate solnerstotug's safety, tolerability, pharmacokinetics, pharmacodynamics, and efficacy, both as a monotherapy and in combination with Regeneron's PD-1 inhibitor Libtayo® [4][5] Clinical Trial Progress - As of January 1, 2025, 45 patients have been enrolled in the dose expansion portion of the trial, with an expected total of approximately 60 patients by the end of Q1 2025 [5] - The company anticipates reporting data from evaluable patients in Q2 2025, including follow-up data from dose escalation cohorts [5] Financial Position - Sensei Biotherapeutics has a cash runway projected into the second quarter of 2026, allowing for the advancement of solnerstotug through the completion of the Phase 1 portion of the study [2][5]
Sensei Biotherapeutics Provides Corporate Update and Highlights Key Upcoming Milestones